Xponance Inc. Purchases 209 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Xponance Inc. grew its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 5.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,924 shares of the company’s stock after acquiring an additional 209 shares during the quarter. Xponance Inc.’s holdings in Inspire Medical Systems were worth $525,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of INSP. UBS Group AG raised its holdings in shares of Inspire Medical Systems by 7.7% in the 4th quarter. UBS Group AG now owns 33,173 shares of the company’s stock worth $6,748,000 after acquiring an additional 2,366 shares during the last quarter. Hsbc Holdings PLC raised its stake in shares of Inspire Medical Systems by 15.9% in the fourth quarter. Hsbc Holdings PLC now owns 21,185 shares of the company’s stock worth $4,313,000 after purchasing an additional 2,905 shares during the last quarter. TD Asset Management Inc bought a new position in shares of Inspire Medical Systems in the fourth quarter valued at approximately $1,953,000. Allianz Asset Management GmbH boosted its position in shares of Inspire Medical Systems by 9.6% during the fourth quarter. Allianz Asset Management GmbH now owns 19,355 shares of the company’s stock valued at $3,937,000 after buying an additional 1,692 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its position in shares of Inspire Medical Systems by 1.0% during the fourth quarter. Treasurer of the State of North Carolina now owns 12,750 shares of the company’s stock valued at $2,594,000 after buying an additional 120 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Price Performance

NYSE:INSP opened at $211.05 on Tuesday. The company has a market capitalization of $6.27 billion, a P/E ratio of -383.73 and a beta of 1.33. The business has a fifty day simple moving average of $184.45 and a two-hundred day simple moving average of $182.54. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.46. The business had revenue of $195.89 million for the quarter, compared to analysts’ expectations of $189.08 million. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The firm’s quarterly revenue was up 29.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.41) EPS. As a group, analysts anticipate that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Leerink Partners raised their price objective on Inspire Medical Systems from $167.00 to $197.00 and gave the company a “market perform” rating in a research note on Tuesday, September 10th. KeyCorp lowered their target price on shares of Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Robert W. Baird cut their price target on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Truist Financial reiterated a “buy” rating and issued a $240.00 price objective (up previously from $217.00) on shares of Inspire Medical Systems in a research note on Monday. Finally, Morgan Stanley dropped their target price on shares of Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $216.62.

Insider Activity

In related news, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total value of $176,000.00. Following the completion of the transaction, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Shawn Mccormick sold 800 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the sale, the director now owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Randy Ban sold 4,861 shares of Inspire Medical Systems stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $188.55, for a total value of $916,541.55. Following the transaction, the insider now directly owns 3,056 shares of the company’s stock, valued at approximately $576,208.80. The disclosure for this sale can be found here. Insiders have sold a total of 5,692 shares of company stock valued at $1,099,207 over the last quarter. Company insiders own 4.10% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.